Ace Indian shuttler P V Sindhu clinched her second women’s singles title of the season with a straight game win over Thailand’s Busanan Ongbamrungphan but HS Prannoy went down fighting in the men’s singles final at the Swiss Open Super 300 badminton tournament in Basel on Sunday.
Playing her second successive final in the tournament, Sindhu, a double Olympic medallist, took 49 minutes to get the better of the fourth seeded Busanan 21-16 21-8.
However, Prannoy suffered a 12-21 18-21 defeat against Asian Games gold medallist and fourth seed Jonatan Christie of Indonesia in a 48-minute summit clash to finish runner-up.
For Sindhu, it was a moment of glory as she finally lifted the trophy after losing to Rio Olympics gold medallist Carolina Marin of Spain in the final of last edition.
The 26-year-old from Hyderabad has happy memories of this venue as she had also claimed the World Championships gold in 2019.
On Sunday, Sindhu registered her 16th win over Busanan in 17 meetings, having lost to the Thai only once—at the 2019 Hong Kong Open, to claim the Super 300 crown, the second lowest tier of BWF Tour events.
Sindhu had won the Syed Modi International Super 300 in Lucknow in January this year.
Sindhu rode on her attack to open up a 3-0 lead but Busanan started to stay in the rallies and produced some good quality shots to make it 7-7.
Busanan tried to keep Sindhu away from the net initially, making her move across the court but the Thai was erratic in her finishing, allowing the Indian to go into the break with a narrow two-point lead.
Busanan used her deceptions and drop shots to dictate the rallies but Sindhu relied on her retrieval skills to stay ahead.
A precise return at the backline gave Sindhu four game points and she sealed the first game when Busanan went wide.
Busanan struggled with her length after the change of sides to concede a 0-5 lead early on in the second game. Sindhu looked more aggressive as she troubled the Thai with her acute angle shots to dictate terms.
In full flow, the Indian soon cruised to a decisive nine-point advantage at the interval. She kept a firm grip on the match to gallop to 18-4, riding on her alert front court play and precise returns.
Busanan continued to hit wide and long to eventually hand over 16 match points to the Indian, who pocketed the game and the match comfortably.
Prannoy, a former world number 8, finished a creditable second best after making his first final in the last five years.
The 29-year-old from Thiruvananthapuram has been grappling with multiple health issues after being diagnosed with a gastroesophageal reflux disease in 2018 and Covid-19 infection in 2019.
On Sunday, Prannoy couldn’t match the accuracy and power of Jonatan, who looked in complete control of the final.
The Indian looked competitive in the early part of the opening game as he quickly erased the early 1-4 deficit and moved to 5-5 but Jonatan pulled away from 8-8 to take a three-point cushion at the breather.
Prannoy was erratic while Jonatan looked rock solid in his defence as the Indonesian created a huge gap with a seven-point burst to grab seven game points. The Indian saved two before conceding the opening game.
The second game was a close affair as the duo moved together till 7-7 before Jonatan again opened up a 11-7 lead at the interval.
Prannoy was not able to sustain the pressure in the rallies, while Jonatan was composed and was rewarded more often for his cross court smashes and fine front-court play.
The Indian did well to claw his way back to 13-13 but a reversal slice helped Jonatan break the run of points.
The momentum shifted again as Jonatan led 19-14 with Prannoy committing a slew of errors. Another winner gave the Indonesian five championship point. Prannoy saved three before hitting the net.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.